Correlation between histogram-based DCE-MRI parameters and 18F-FDG PET values in oropharyngeal squamous cell carcinoma: Evaluation in primary tumors and metastatic nodes.
Aged
Cohort Studies
Contrast Media
/ metabolism
Female
Fluorodeoxyglucose F18
/ metabolism
Humans
Lymph Nodes
/ pathology
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Oropharyngeal Neoplasms
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
/ methods
Positron-Emission Tomography
/ methods
Radiopharmaceuticals
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ diagnostic imaging
Tomography, X-Ray Computed
/ methods
Tumor Burden
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
10
2019
accepted:
10
02
2020
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
24
6
2020
Statut:
epublish
Résumé
To investigate the correlation between histogram-based Dynamic Contrast-Enhanced magnetic resonance imaging (DCE-MRI) parameters and positron emission tomography with 18F-fluorodeoxyglucose (18F-FDG-PET) values in oropharyngeal squamous cell carcinoma (OPSCC), both in primary tumors (PTs) and in metastatic lymph nodes (LNs). 52 patients with a new pathologically-confirmed OPSCC were included in the present retrospective cohort study. Imaging including DCE-MRI and 18F-FDG PET/CT scans were acquired in all patients. Both PTs and the largest LN, if present, were volumetrically contoured. Quantitative parameters, including the transfer constants, Ktrans and Kep, and the volume of extravascular extracellular space, ve, were calculated from DCE-MRI. The percentiles (P), P10, P25, P50, P75, P90, and skewness, kurtosis and entropy were obtained from the histogram-based analysis of each perfusion parameter. Standardized uptake values (SUV), SUVmax, SUVpeak, SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated applying a SUV threshold of 40%. The correlations between all variables were investigated with the Spearman-rank correlation test. To exclude false positive results under multiple testing, the Benjamini-Hockberg procedure was applied. No significant correlations were found between any parameters in PTs, while significant associations emerged between Ktrans and 18F-FDG PET parameters in LNs. Evident relationships emerged between DCE-MRI and 18F-FDG PET parameters in OPSCC LNs, while no association was found in PTs. The complex relationships between perfusion and metabolic biomarkers should be interpreted separately for primary tumors and lymph-nodes. A multiparametric approach to analyze PTs and LNs before treatment is advisable in head and neck squamous cell carcinoma (HNSCC).
Identifiants
pubmed: 32119697
doi: 10.1371/journal.pone.0229611
pii: PONE-D-19-29908
pmc: PMC7051076
doi:
Substances chimiques
Contrast Media
0
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0229611Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nucl Med Commun. 2014 Jan;35(1):30-5
pubmed: 24121312
PLoS One. 2019 Feb 28;14(2):e0213111
pubmed: 30818360
Nucl Med Commun. 2017 Dec;38(12):1076-1084
pubmed: 28885542
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Transl Oncol. 2018 Apr;11(2):498-503
pubmed: 29510360
Oral Oncol. 2018 Mar;78:137-144
pubmed: 29496041
Cancer Med. 2015 Jul;4(7):1101-16
pubmed: 25919147
Cancers (Basel). 2019 Apr 15;11(4):
pubmed: 30991696
PLoS One. 2015 Aug 13;10(8):e0134749
pubmed: 26270054
Contrast Media Mol Imaging. 2019 Jan 2;2019:5081909
pubmed: 30718984
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2122-2138
pubmed: 29948105
AJNR Am J Neuroradiol. 2003 Mar;24(3):301-11
pubmed: 12637272
Eur J Radiol. 2015 Jul;84(7):1269-76
pubmed: 25958189
ORL J Otorhinolaryngol Relat Spec. 2001 Sep-Oct;63(5):307-13
pubmed: 11528276
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1680-1693
pubmed: 29696443
Eur Radiol. 2010 Oct;20(10):2358-66
pubmed: 20443116
Transl Oncol. 2019 Jan;12(1):8-14
pubmed: 30240972
Head Neck. 2014 Mar;36(3):323-7
pubmed: 23729374
Acta Oncol. 2015;54(9):1408-15
pubmed: 26256482
Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):9-17
pubmed: 27511842
Magn Reson Imaging Clin N Am. 2016 Feb;24(1):123-133
pubmed: 26613878
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):969-977
pubmed: 29428251
Oral Oncol. 2009 Jul;45(7):621-6
pubmed: 19027349
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1403-10
pubmed: 19906496
Head Neck. 2019 Feb;41(2):366-373
pubmed: 30548704
PLoS One. 2018 Sep 6;13(9):e0202897
pubmed: 30188926
Laryngoscope. 2019 Apr;129(4):877-882
pubmed: 30194702
Anticancer Res. 2018 Mar;38(3):1637-1642
pubmed: 29491096
Med Oncol. 2016 Dec;33(12):138
pubmed: 27817107
Contrast Media Mol Imaging. 2017 Oct 19;2017:5369625
pubmed: 29114177
PLoS One. 2013 Sep 13;8(9):e75094
pubmed: 24058651
Transl Oncol. 2017 Feb;10(1):17-21
pubmed: 27888709
Eur Arch Otorhinolaryngol. 2018 Jul;275(7):1845-1851
pubmed: 29748768
Br J Radiol. 2016 Nov;89(1067):20160217
pubmed: 27416996
Clin Nucl Med. 2014 Mar;39(3):225-31
pubmed: 24152652
Clin Radiol. 2018 Aug;73(8):757.e21-757.e27
pubmed: 29779759
Front Oncol. 2019 Nov 14;9:1118
pubmed: 31799173
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1383-1392
pubmed: 28315948
AJR Am J Roentgenol. 2016 Aug;207(2):248-56
pubmed: 27163282
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):299-307
pubmed: 21236594
Head Neck. 2016 Apr;38(4):529-35
pubmed: 25352335
Surg Oncol Clin N Am. 2015 Jul;24(3):455-71
pubmed: 25979394
Clin Lung Cancer. 2019 Nov;20(6):420-428
pubmed: 31300363
J Magn Reson Imaging. 1999 Sep;10(3):223-32
pubmed: 10508281
Medicine (Baltimore). 2015 Nov;94(47):e2141
pubmed: 26632740
Crit Rev Oncol Hematol. 2016 Jul;103:27-36
pubmed: 27221393